secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001683168-23-005515
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma Q2 net loss $2.5M; PH-762 Phase 1b trial advancing after IND clearance
--------------------------------------------------------------------------------

- Net loss of $2.5M ($1.47 per share) for Q2 2023, consistent with $2.5M ($2.22 per share) in Q2 2022.
- Cash $11.3M at June 30, 2023 vs $11.8M at Dec 31, 2022; R&D expenses $1.4M, up 6% YoY.
- FDA cleared IND for PH-762; planning Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, Merkel cell.
- Initiated collaborative Phase 1b trial with AgonOx's TIL program (AGX148) and Providence Cancer Institute.
- Appointed Jennifer Phillips, Pharm.D., as VP of Regulatory Affairs and Corporate Affairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823005515/0001683168-23-005515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823005515/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-005515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer